“Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 ”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 2, Mar. 2022, p. s2, https://doi.org/10.25251/skin.6.supp.2.